MARKET

AWH

AWH

Aspira Women`s Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.680
+0.130
+3.66%
Pre Market: 3.770 +0.09 +2.45% 08:00 09/24 EDT
OPEN
3.570
PREV CLOSE
3.550
HIGH
3.830
LOW
3.530
VOLUME
8
TURNOVER
--
52 WEEK HIGH
10.54
52 WEEK LOW
2.466
MARKET CAP
412.41M
P/E (TTM)
-16.9195
1D
5D
1M
3M
1Y
5Y
Aspira Women’s Health Inc. to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
AUSTIN, Texas, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, Sept...
GlobeNewswire · 3d ago
Abortion providers urge U.S. Supreme Court to uphold Roe v. Wade landmark
reuters.com · 09/13 19:25
Soccer-Chelsea's Kerr keen to return to Australia once restrictions lifted
reuters.com · 09/12 03:35
Aspira Women’s Health Kicks Off Ovarian Cancer Awareness Month by Further Establishing Itself as a Thought Leader in Ovarian Cancer
Signals Call to Action for Immediate Progress in Conquering Ovarian CancerAUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heralding the beginning of Ovarian Cancer Awareness Month, Aspira Women’s Health, Inc (“Aspira”) (Nasdaq: AWH) will ring the closing...
GlobeNewswire · 09/09 12:00
Aspira Women's Health Inc. (NASDAQ:AWH) insiders placed bullish bets worth US$2.7m in the last 12 months
Quite a few insiders have dramatically grown their holdings in Aspira Women's Health Inc. ( NASDAQ:AWH ) over the past...
Simply Wall St. · 09/04 12:30
Aspira Women's Health Reports Second Quarter 2021 Financial Results
Total Revenue Increased 141% to $1.8 million; OVA1 Volume Grew 85% to 4,553 Accessions
GlobeNewswire · 08/12 20:05
Aspira (AWH) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/12 09:23
Analysts Estimate Aspira (AWH) to Report a Decline in Earnings: What to Look Out for
Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/05 19:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AWH. Analyze the recent business situations of Aspira Women`s Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AWH stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 108
Institutional Holdings: 35.43M
% Owned: 31.62%
Shares Outstanding: 112.07M
TypeInstitutionsShares
Increased
22
1.09M
New
20
2.01M
Decreased
31
2.50M
Sold Out
22
918.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
James Lafrance
President/Chief Executive Officer/Director
Valerie Palmieri
Chief Financial Officer
Robert Beechey
Independent Director
Sandra Brooks
Independent Director
Veronica Jordan
Independent Director
Nicole Sandford
Declaration Date
Dividend Per Share
Ex-Div Date
05/22/2017
Dividend USD 0
07/07/2017
05/22/2017
Special Dividend USD 5
07/07/2017
About AWH
Aspira Women's Health Inc. is engaged in discovering, developing and commercialization of diagnostic and bio-analytical solutions that help physicians to diagnose, treat and improve gynecologic health outcomes for women. Its products include OVA1, Overa and OVA1plus. OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at high-risk of having a malignant ovarian tumor prior to planned surgery. OVERA is a second-generation biomarker panel intended to maintain OVA1's high sensitivity while improving specificity. OVA1plus is a reflex offering, which uses OVA1 primarily and OVERA as a confirmation for OVA1 intermediate range results. It is also developing three additional products and related services, including two diagnostic algorithms, OVASight and EndoCheck, and a high-risk diagnostic algorithm, OVAInherit, for patients with or without a pelvic mass who are genetically predisposed to ovarian cancer.

Webull offers kinds of Aspira Women's Health Inc stock information, including NASDAQ:AWH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AWH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AWH stock methods without spending real money on the virtual paper trading platform.